IMS 2023 | Practical considerations when treating patients with WM: exciting agents & combinations
Steven Treon
• 29 Sep 2023
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses practical considerations when treating patients with Waldenström’s macroglobulinemia (WM), highlighting promising therapies available for patients. Dr Treon also comments on the importance of optimizing BTK inhibitor use and the sequencing of novel agents to improve outcomes for these patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
